Copyright: ©Author(s) 2026.
World J Gastroenterol. Jun 7, 2026; 32(21): 116581
Published online Jun 7, 2026. doi: 10.3748/wjg.v32.i21.116581
Published online Jun 7, 2026. doi: 10.3748/wjg.v32.i21.116581
Table 1 Baseline demographic and laboratory characteristics, n (%)/medians (interquartile range)
| Early PC | Late PC | CP | H | P value1 | |
| n | 149 | 152 | 52 | 61 | |
| Age (years) | 62 (53-69) | 60 (51-68) | 62 (52-70) | 61 (53-67) | 0.646 |
| Sex | 0.907 | ||||
| Male | 86 (57.7) | 86 (56.6) | 27 (51.9) | 35 (57.4) | |
| Female | 63 (42.3) | 66 (43.4) | 25 (48.1) | 26 (42.6) | |
| Cancer histology type | 0.999 | ||||
| Ductal adenocarcinoma | 136 (91.3) | 139 (91.4) | |||
| Neuroendocrine carcinoma | 4 (2.7) | 4 (2.6) | |||
| Others2 | 9 (4.0) | 9 (5.9) | |||
| TNM classification | |||||
| Stage I | 9 | ||||
| Stage II | 140 | ||||
| Stage III | 53 | ||||
| Stage IV | 99 | ||||
| Underlying DM | 60 (40.3) | 53 (34.9) | 17 (32.7) | 0 (0.0) | < 0.001 |
| Smoking status | 0.181 | ||||
| Ex-smoker | 9 (6.0) | 14 (9.2) | 6 (11.5) | 7 (11.5) | |
| Non-smoker | 102 (68.5) | 89 (58.6) | 27 (51.9) | 42 (68.9) | |
| Smoker | 38 (25.5) | 49 (32.2) | 19 (36.5) | 12 (19.7) | |
| Presence of other malignancy | 6 (4.0) | 6 (3.9) | 6 (11.5) | 1 (1.6) | 0.066 |
| Serum markers | |||||
| S100A6 (ng/mL) | 61.4 (18.8-114.2) | 43.6 (19.7-101.3) | 22.9 (11.9-41.9) | 21.2 (13.3-37.0) | < 0.001 |
| CA19-9 (U/mL) | 100.6 (23.0-493.7) | 282.6 (25.9-3118.7) | 14.5 (6.8-30.4) | 7.9 (4.0-12.5) | < 0.001 |
| CEA (ng/mL) | 2.1 (1.3-3.4) | 3.0 (1.4-10.0) | 2.2 (1.6-3.6) | 1.2 (0.9-1.6) | < 0.001 |
Table 2 Univariate and multivariate binary logistic regression analysis for distinguishing pancreatic cancer from chronic pancreatitis and healthy controls
| Univariate binary logistic regression | Multivariate binary logistic regression | |||
| OR (95%CI) | P value | OR (95%CI) | P value | |
| Age | 1.00 (0.98-1.02) | 0.972 | ||
| Sex | 0.91 (0.59-1.41) | 0.677 | ||
| Underlying DM | 3.39 (1.93-5.98) | < 0.001 | 1.85 (0.94-3.63) | 0.075 |
| Smoking status | ||||
| Ex-smoker vs non-smoker | 0.64 (0.31-1.33) | 0.232 | ||
| Smoker vs non-smoker | 1.01 (0.62-1.66) | 0.957 | ||
| Other malignancy | 0.63 (0.24-1.64) | 0.342 | ||
| Serum markers | ||||
| S100A6 | 1.82 (1.46-2.26) | < 0.001 | 1.82 (1.40-2.37) | < 0.001a |
| CA19-9 | 2.25 (1.85-2.72) | < 0.001 | 2.21 (1.80-2.72) | < 0.001a |
| CEA | 6.51 (2.82-15.06) | < 0.001 | 1.52 (0.51-4.55) | 0.454 |
- Citation: Bae GE, Kim SM, Lee JK, Lee SY. First large-scale prospective evaluation of serum S100A6 as a complementary biomarker for early pancreatic cancer detection. World J Gastroenterol 2026; 32(21): 116581
- URL: https://www.wjgnet.com/1007-9327/full/v32/i21/116581.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i21.116581